Cumberland Pharmaceuticals Inc. (CPIX) 주식 분석

회사 개요

Cumberland Pharmaceuticals Inc. operates as a specialty pharmaceutical entity dedicated to the acquisition, development, and commercialization of prescription products designed for specific therapeutic indications. The company functions within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which focuses on creating specialized formulations rather than mass-market generic drugs. As of the latest reporting period, Cumberland holds a market capitalization of $46.52M, generates annual revenue of $44.52M, and employs a workforce of 93 individuals. These financial figures indicate that Cumberland is a small-cap company with a valuation that reflects a niche market position rather than broad-scale dominance, suggesting a business model reliant on high-margin specialty products to drive profitability in a competitive landscape.

재무 건전성

The company reported revenue of $44.52M over the trailing twelve months, while net income stood at -$2,836,128 and EBITDA reached $1.35M, revealing a significant operational loss despite positive earnings before interest, taxes, depreciation, and amortization. The substantial gap between the positive EBITDA and negative net income highlights a cost structure where interest expenses or other non-operational costs are eroding operating profits. Cumberland maintains a free cash flow of $6.44M, which provides a crucial buffer for financial flexibility, allowing the firm to fund operations or strategic initiatives without relying solely on external financing. Profitability metrics show a gross margin of 85.0%, indicating high pricing power or low cost of goods sold, contrasted by an operating margin of -10.0% and a profit margin of -6.4%, which signal that overhead costs are currently outweighing gross profits. Liquidity analysis shows the company holds $11.44M in cash against $10.18M in debt, resulting in a debt-to-equity ratio of 41.48%, which suggests a leveraged balance sheet where liabilities are substantial relative to shareholder equity. The current ratio of 1.01 indicates that current assets barely cover current liabilities, pointing to tight short-term liquidity conditions that require careful management of working capital. Return on Equity is -12.2% and Return on Assets is -2.3%, metrics that reveal management is currently generating losses rather than returns on the capital invested in the business.

밸류에이션 평가

Valuation metrics show a P/E Ratio (TTM) of N/A due to the lack of earnings, while the Forward P/E is listed at 22.21, implying market expectations for future profitability that have not yet materialized in historical data. The price-to-book ratio stands at 1.87, suggesting the market values the company at a 87% premium over its tangible book value, which often reflects intangible assets like intellectual property or pipeline potential. Alternative valuation measures include a price-to-sales ratio of 1.04 and an EV/EBITDA of 33.19, which provide context for valuation when traditional earnings multiples are unavailable due to losses. The stock has exhibited volatility with a 52-week high of $6.27 and a 52-week low of $1.85, placing the trading range within a wide band that reflects significant price discovery. The beta value of -0.33 indicates a unique inverse correlation to the broader market, meaning the stock tends to move counter to general market trends rather than with them. These metrics collectively paint a picture of a high-risk, high-reward asset that trades at a premium relative to its book value but faces significant earnings uncertainty.

Growth & Income

Revenue growth for the year-over-year period is recorded at 31.1%, while earnings growth is N/A, indicating that top-line expansion is outpacing any potential for profit generation in the current period. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all earnings rather than distributing them to shareholders. This reinvestment strategy suggests that management prioritizes funding operations or research over returning capital, which is typical for early-stage specialty pharmaceutical companies seeking to expand their product portfolio. The overall growth and income profile is characterized by strong top-line momentum supported by significant free cash flow, yet tempered by negative net income and a lack of dividend income for investors.